The Food and Drug Administration (FDA) recently approved Keytruda (pembrolizumab) plus chemoradiotherapy (CRT) for the treatment of patients with stages 3 to 4A cervical cancer. The first approval of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback